151 related articles for article (PubMed ID: 19317653)
1. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
4. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
5. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
Nagele F; Petru E; Medl M; Kainz C; Graf AH; Sevelda P
Obstet Gynecol; 1995 Aug; 86(2):259-64. PubMed ID: 7617357
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
[TBL] [Abstract][Full Text] [Related]
11. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
12. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
13. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
[TBL] [Abstract][Full Text] [Related]
15. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
Meisel M; Straube W; Weise J; Burkhardt B
Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
[TBL] [Abstract][Full Text] [Related]
16. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
[TBL] [Abstract][Full Text] [Related]
17. CA 15-3 serum levels in ovarian cancer.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
[TBL] [Abstract][Full Text] [Related]
18. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum CA-125 levels in borderline tumors of the ovary.
Rice LW; Lage JM; Berkowitz RS; Goodman A; Muto MG; Knapp RC; Bell DA
Gynecol Oncol; 1992 Aug; 46(2):226-9. PubMed ID: 1500026
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.
Scambia G; Testa U; Benedetti Panici P; Foti E; Martucci R; Gadducci A; Perillo A; Facchini V; Peschle C; Mancuso S
Br J Cancer; 1995 Feb; 71(2):354-6. PubMed ID: 7841052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
